Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Other Non Operating Income: 2018-2024

Historic Other Non Operating Income for Arcturus Therapeutics Holdings (ARCT) over the last 7 years, with Dec 2024 value amounting to $15.2 million.

  • Arcturus Therapeutics Holdings' Other Non Operating Income fell 15.30% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.8 million, marking a year-over-year decrease of 26.17%. This contributed to the annual value of $15.2 million for FY2024, which is 55.25% down from last year.
  • According to the latest figures from FY2024, Arcturus Therapeutics Holdings' Other Non Operating Income is $15.2 million, which was down 55.25% from $34.0 million recorded in FY2023.
  • In the past 5 years, Arcturus Therapeutics Holdings' Other Non Operating Income registered a high of $34.0 million during FY2023, and its lowest value of -$1.9 million during FY2021.
  • In the last 3 years, Arcturus Therapeutics Holdings' Other Non Operating Income had a median value of $15.2 million in 2024 and averaged $16.2 million.
  • Its Other Non Operating Income has fluctuated over the past 5 years, first tumbled by 432.13% in 2021, then skyrocketed by 5,777.76% in 2023.
  • Over the past 5 years, Arcturus Therapeutics Holdings' Other Non Operating Income (Yearly) stood at -$361,000 in 2020, then tumbled by 432.13% to -$1.9 million in 2021, then spiked by 68.87% to -$598,000 in 2022, then soared by 5,777.76% to $34.0 million in 2023, then crashed by 55.25% to $15.2 million in 2024.